



29 June 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

MEDLAB COMPLETES FIRST ORDER OF NEW CANNABINOID TO UK UNDER US/UK AGREEMENT

- 4th cannabinoid product developed and manufactured – Magnesium and CBD (Mg Optima Relax + CBD)
- Manufactured and to be exported under licence to the UK
- First order of 5,000 units

Medlab Clinical Ltd (ASX: MDC) is pleased to announce its first order of 5,000 units of its newly developed hybrid cannabinoid (Mg Optima Relax + CBD) has been manufactured for Cultech Ltd in the UK, and as per the agreement is awaiting an “ex-works” collection.

As per the ASX announcement on 12 December 2019, Medlab executed an exclusive distribution agreement to expand into the UK. Part of the agreement was the supply of a cannabinoid product combining Mg Optima Relax, a current Medlab nutraceuticals formulation available in Australian Pharmacies and CBD that is used in the NanoCBD™ manufacture. The product was developed in the USA and manufactured by American Nutritional Corp Inc.

After several months of development, the product has been manufactured in accordance to Cultech’s requirements.

Dr Sean Hall, CEO of Medlab states “this is our first meaningful export for this trade agreement, and I see this as a start of great potential as we develop UK markets.”

Magnesium (Mg) has well known benefits for stress reduction, sleep, and mitigating restless legs. Mg Optima Relax as a nutraceutical (that being with no CBD) is well placed in the Australian marketplace as a Medlab nutraceutical.

The combination of the 2 formulations (Mg Optima Relax and CBD) adds to the overall story of promoting relaxation and reducing stress.

Dr Hall added, “this product is not for Australia because of our laws relating to CBD use, but primed for other global legal markets. We would envisage a more global play regarding this product, as most Westerners are well versed in the benefits of magnesium, and hence its relatively easy to understand the synergistic benefits of combining Magnesium and CBD.”

Established in 1994, Cultech has become internationally recognised as both an innovator and premium quality manufacturer within the nutritional supplement industry. The powerful combination of research scientists together with formulation, process and production technologies enables Cultech to provide a fully integrative manufacturing service, involving unique formulations, innovative presentation and high-quality finished products.

For and behalf of the Board.



Dr Sean Hall
Managing Director

ISSUED FOR:	MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co
FOR FURTHER	DR SEAN HALL, CEO, MEDLAB CLINICAL
INFORMATION:	TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.